Exploiting the enhanced permeability and retention effect for tumor targeting

被引:1451
作者
Iyer, Arun K.
Khaled, Greish
Fang, Jun
Maeda, Hiroshi [1 ]
机构
[1] Sojo Univ, Fac Pharmaceut Sci, Lab Microbiol & Oncol, Ikeda, Osaka 8620082, Japan
[2] Kumamoto Univ, Cooperat Res Ctr, BioDynam Res Lab, Mashiki, Kumamoto 8600811, Japan
关键词
D O I
10.1016/j.drudis.2006.07.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Of the tumor targeting strategies, the enhanced permeability and retention (EPR) effect of macromolecules is a key mechanism for solid tumor targeting, and considered a gold standard for novel drug design. In this review, we discuss various endogenous factors that can positively impact the EPR effect in tumor tissues. Further, we discuss ways to augment the EPR effect by use of exogenous agents, as well as practical methods available in the clinical setting. Some innovative examples developed by researchers to combat cancer by the EPR mechanism are also discussed.
引用
收藏
页码:812 / 818
页数:7
相关论文
共 81 条
[1]   8-Nitroguanosine formation in viral pneumonia and its implication for pathogenesis [J].
Akaike, T ;
Okamoto, S ;
Sawa, T ;
Yoshitake, J ;
Tamura, F ;
Ichimori, K ;
Miyazaki, K ;
Sasamoto, K ;
Maeda, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (02) :685-690
[2]  
Courtice FC, 1963, LYMPH LYMPHATIC SYST, P89
[3]  
Doi K, 1996, CANCER-AM CANCER SOC, V77, P1598, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1598::AID-CNCR27>3.0.CO
[4]  
2-U
[5]   The dawning era of polymer therapeutics [J].
Duncan, R .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) :347-360
[6]  
Fang J, 2003, CANCER RES, V63, P3567
[7]  
Fang J, 2002, CANCER RES, V62, P3138
[8]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[9]   Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy [J].
Gabizon, AA .
CANCER INVESTIGATION, 2001, 19 (04) :424-436
[10]   Pegaspargase: a review of clinical studies [J].
Graham, ML .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (10) :1293-1302